BIG
HRTX icon

Brooklyn Investment Group’s Heron Therapeutics HRTX Stock Holding History

Brooklyn Investment Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.7K Buy
+15,927
New +$18.5K ﹤0.01% 1825
2025
Q3 		– Sell
-364
Closed -$754 – 1577
2025
Q2 		$754 Buy
+364
New +$743 ﹤0.01% 3005

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Brooklyn Investment Group's HRTX Position: Q1 2026 in Review

Brooklyn Investment Group opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 15,927 shares worth $12.7K. The stake represents ﹤0.01% of the portfolio and ranks #1825 among its holdings. This is a return to the name: Brooklyn Investment Group previously reported a position in HRTX as recently as Q2 2025.

Brooklyn Investment Group first reported a position in HRTX in Q2 2025 and has held it in 2 quarters since. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Brooklyn Investment Group held 15,927 shares of Heron Therapeutics worth $12.7K as of Q1 2026.
  • Heron Therapeutics was a new Brooklyn Investment Group position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Brooklyn Investment Group's portfolio in Q1 2026, its #1825 holding.
  • Brooklyn Investment Group first reported a position in Heron Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.